Effects of glucagon-like peptide-1 (7-36)amide on motility and sensation of the proximal stomach in humans

被引:91
|
作者
Schirra, J
Wank, U
Arnold, R
Göke, B
Katschinski, M
机构
[1] Univ Marburg, Dept Gastroenterol & Endocrinol, Marburg, Germany
[2] Univ Munich, Dept Gastroenterol, Munich, Germany
关键词
D O I
10.1136/gut.50.3.341
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Glucagon-like peptide-1 (7-36)amide (GLP-1) retards gastric emptying, reduces food intake, and inhibits antroduodenal and stimulates pyloric motility. Aims: To assess the effects of synthetic GLP-1 on fundus tone and volume waves, gastric compliance, and perception of gastric distension. Subjects: Eleven healthy male volunteers. Methods: Background infusions were saline, or GLP-1 at 0.3 or 0.9 pmol/kg/min on separate days in random order. Interdigestive fundus motility was recorded by barostat (maximum capacity of intragastric bag 1200 ml) during basal and peptide periods of 60 minutes each. Thereafter stepwise isobaric distensions were performed with ongoing peptide infusion, and gastric sensation was scored. Results: Low and high loads of GLP-1 induced physiological and supraphysiological plasma immunoreactivities, respectively. GLP-1 dose dependently diminished fundus tone (162.9 (15.0) and 259.5 (17.2) v 121.1 (6.0) ml with saline; p<0.0001). It greatly reduced volume waves and total volume displaced by these events (p<0.0001). Gastric compliance derived from isobaric distension rose in a dose related manner (42.6 (5.5) and 63.6 (7.7) v 27.0 (3.5) ml/mm Hg; p=0.0004) with a concomitant reduction of the pressure at half maximum bag volume (6.4 (0.4) and 5.5 (0.4) v 7.2 (0.1) mm Hg; p<0.0001). GLP-1 did not change perception of isobaric distension but reduced the perception score related to corresponding bag volume (p<0.0001). Conclusions: GLP-1 is a candidate physiological inhibitory regulator of fundus motility. It allows the stomach to afford a larger volume without increase in sensation.
引用
收藏
页码:341 / 348
页数:8
相关论文
共 50 条
  • [41] Subcutaneous glucagon-like peptide-1 (7-36) amide causes hypoglycaemia in fasted healthy subjects.
    Edwards, CM
    Todd, J
    Ghatei, M
    Bloom, S
    [J]. DIABETES, 1997, 46 : 712 - 712
  • [42] Gene expression profiling of isolated islets of Langerhans treated with glucagon-like peptide-1 (7-36 amide)
    Nolan, AL
    Lechner, A
    Blacken, RA
    Habener, JF
    [J]. DIABETOLOGIA, 2004, 47 : A161 - A162
  • [43] SOLUBILIZATION OF ACTIVE RECEPTORS FOR GLUCAGON-LIKE PEPTIDE-1 (7-36)AMIDE FROM RAT LUNG MEMBRANES
    GOKE, R
    KOLLIGS, F
    RICHTER, G
    LANKATBUTTGEREIT, B
    GOKE, B
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 264 (02): : L146 - L152
  • [44] EFFECTS OF GLUCAGON-LIKE PEPTIDE-1(7-36) AMIDE ON THE CYTOPLASMIC CA-2+-CONCENTRATION IN RAT ISLET CELLS
    FRIDOLF, T
    AHREN, B
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1993, 96 (1-2) : 85 - 90
  • [45] The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride
    Seeley, RJ
    Blake, K
    Rushing, PA
    Benoit, S
    Eng, J
    Woods, SC
    D'Alessio, D
    [J]. JOURNAL OF NEUROSCIENCE, 2000, 20 (04): : 1616 - 1621
  • [46] Effect of glucagon-like peptide-1(7-36)-amide on initial splanchnic glucose uptake and insulin action in humans with type 1 diabetes
    Vella, A
    Shah, P
    Basu, R
    Basu, A
    Camilleri, M
    Schwenk, FW
    Holst, JJ
    Rizza, RA
    [J]. DIABETES, 2001, 50 (03) : 565 - 572
  • [47] EFFECTS OF SUBCUTANEOUS GLUCAGON-LIKE PEPTIDE-1 (GLP-1[7-36 AMIDE]) IN PATIENTS WITH TYPE-2-DIABETES
    NAUCK, MA
    WOLLSCHLAGER, D
    WERNER, J
    HOLST, JJ
    ORSKOV, C
    CREUTZFELDT, W
    WILLMS, B
    [J]. DIABETOLOGIA, 1995, 38 : A39 - A39
  • [48] GLUCAGON-LIKE PEPTIDE-1 7-36, A NEW BRAIN-GUT HORMONE
    KREYMANN, B
    KANSE, S
    GHATEI, MA
    WILLIAMS, G
    BLOOM, SR
    [J]. REGULATORY PEPTIDES, 1988, 22 (04) : 414 - 414
  • [49] Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
    Nauck, MA
    Wollschlager, D
    Werner, J
    Holst, JJ
    Orskov, C
    Creutzfeldt, W
    Willms, B
    [J]. DIABETOLOGIA, 1996, 39 (12) : 1546 - 1553
  • [50] Different effects of glucagon-like peptide-1 (7-36) on apoptosis of macrophages with different activation states
    Tang, Xiaohan
    Lei, Kang
    Li, Xia
    Zhou, Zhiguang
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2016, 32 (SUPP 2) : 66 - 67